CytomX Therapeutics (CTMX) Stock Forecast & Price Target

$0.96 +0.07 (+7.90%)

(As of 11/25/2024 ET)

CytomX Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 6 Analyst Ratings

Sell
0

Hold
3

Buy
3

Based on 6 Wall Street analysts who have issued ratings for CytomX Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 6 analysts, 3 have given a hold rating, and 3 have given a buy rating for CTMX.

Consensus Price Target

$5.77
501.11% Upside

According to the 6 analysts' twelve-month price targets for CytomX Therapeutics, the average price target is $5.77. The highest price target for CTMX is $8.00, while the lowest price target for CTMX is $3.50. The average price target represents a forecasted upside of 501.11% from the current price of $0.96.

Get the Latest News and Ratings for CTMX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for CytomX Therapeutics and its competitors.

CTMX Analyst Ratings Over Time

Type	Current Forecast 11/27/23 to 11/26/24	1 Month Ago 10/28/23 to 10/27/24	3 Months Ago 8/29/23 to 8/28/24	1 Year Ago 11/27/22 to 11/27/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)	1 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$5.77	$5.77	$5.77	$2.73
Forecasted Upside	501.11% Upside	460.44% Upside	397.63% Upside	105.26% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold

MUST-SEE: Everyone will be talking about this $2 trillion AI tech boom soon (Ad)

Amazon is making its biggest investment ever… $150 billion to be exact. And one company stands to benefit from this massive capital influx. This company could deliver a huge windfall for investors who get in before this story hits the mainstream, which could happen at any time.

Don't miss out... Click here to reveal Amazon’s Secret Partner.

CTMX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CTMX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

CytomX Therapeutics Stock vs. The Competition

Type	CytomX Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.50	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	501.11% Upside	17,622.81% Upside	6.37% Upside
News Sentiment Rating	Positive News See Recent CTMX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/11/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Neutral
5/28/2024	Piper Sandler 2 of 5 stars		Upgrade	Neutral ➝ Overweight	$2.25 ➝ $3.50	+100.00%
5/9/2024	BMO Capital Markets 4 of 5 stars		Boost Target	Market Perform ➝ Market Perform	$3.25 ➝ $3.59	+55.41%
5/9/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Driscoll Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$3.00 ➝ $8.00	+90.93%
5/6/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$2.50 ➝ $8.00	+80.59%
4/22/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underweight ➝ Neutral
3/28/2023	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral	$4.00 ➝ $2.00	+11.73%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 01:24 AM ET.

CTMX Forecast - Frequently Asked Questions

: According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for CytomX Therapeutics is $5.77, with a high forecast of $8.00 and a low forecast of $3.50.
: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CTMX shares.
: According to analysts, CytomX Therapeutics's stock has a predicted upside of 501.11% based on their 12-month stock forecasts.
: CytomX Therapeutics has been rated by research analysts at HC Wainwright in the past 90 days.
: Analysts like CytomX Therapeutics less than other "medical" companies. The consensus rating score for CytomX Therapeutics is 2.50 while the average consensus rating score for "medical" companies is 2.80. Learn more on how CTMX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

140% Yields From Stocks Like Tesla? Here's How (Black Friday Special) (Ad)

140% Dividends from stocks like Tesla? Discover How for Just $9! For Black Friday, get the full details of an unique dividend strategy that works with giants like Tesla, Apple, and Amazon - at a 82% discount! Don't miss out on this special offer.

Click now to learn how to have the chance at 140% yields before time runs out!

This page (NASDAQ:CTMX) was last updated on 11/26/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CytomX Therapeutics (CTMX) Stock Forecast & Price Target